Roche sales up 10% to €50.7B in Q3

Wednesday, 16. October 2019 07:09

Roche Holding AG said on Wednesday its total sales jumped 10% to €50.7 billion in the first nine months of 2019. The company's sales grew by €4.4 billion from the beginning of the year since it stood at €46.3 billion in December 2018.

Pharmaceutical Division sales rose 12% amid high demand for recently introduced medicines such as Ocrevus, Hemlibra, Tecentriq, and Perjeta. Meanwhile, Diagnostics Division went up 4%.

The United States was the flywheel of the sales rise with a 14% increase to €22.1 billion, while the Basel-based company declined on the European market 1% to €6.9 billion, mainly because of the competition launched similar products.

"The uptake of our newly introduced medicines is very strong. We are successfully entering new disease areas and providing important new treatment options to serve more patients with severe conditions. Based on the strong demand for our new medicines and continued progress of our product pipeline we have raised the outlook for 2019 and I am confident that we will continue to grow beyond this year," Roche CEO Severin Schwan said.

Related Links: Roche Holding
Breaking the News / GA